- NACDS, NCPA, GPhA express support for Drug Quality and Security Act
- 21 health industry groups address FDA on proposed changes to generic drug label rules
- Generic drug prices spike, but PBMs' reimbursement rates don't keep up, NCPA study finds
- Americans more likely than others to prefer generics, study finds
- ROUNDTABLE: Improving patient outcomes, controlling costs with OTCs
GURGAON, India, and PRINCETON, N.J. — Ranbaxy Pharmaceuticals has received final approval for its generic Alzheimer's drug from the Food and Drug Administration, giving the drug maker 180 days of market exclusivity.
Ranbaxy Pharmaceuticals, a subsidiary of Ranbaxy Labs, will manufacture and market donepezil hydrochloride tablets, a generic version of Aricept, in the 5-mg and 10-mg strength in the United States.
"We are pleased to announce the launch of donepezil, which expands Ranbaxy's portfolio of affordable generic pharmaceuticals. Ranbaxy's generic formulation of Aricept will benefit the U.S. healthcare system by providing a more affordable treatment option to patients, which will have a positive impact on escalating U.S. healthcare costs," said Bill Winter, VP trade sales at RPI.